PlainRecalls
FDA Drug Moderate Class II Terminated

Ranitidine Capsules 150 mg, (a) 60 count bottles (NDC 62559-690-60) , (b) 500 count bottles (NDC 62559-690-05), Rx only, Manufactured by: Appco Pharma LLC, Piscataway, NJ 08854, Distributed by: ANI Pharmaceuticals, Inc., Baudette, MN 56623.

Reported: January 15, 2020 Initiated: January 7, 2020 #D-0649-2020

Product Description

Ranitidine Capsules 150 mg, (a) 60 count bottles (NDC 62559-690-60) , (b) 500 count bottles (NDC 62559-690-05), Rx only, Manufactured by: Appco Pharma LLC, Piscataway, NJ 08854, Distributed by: ANI Pharmaceuticals, Inc., Baudette, MN 56623.

Reason for Recall

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Details

Recalling Firm
Appco Pharma LLC
Units Affected
624 bottes
Distribution
Product was distributed to 6 major distributors/wholesalers some with multiple locations who may have further distribute the product.
Location
Piscataway, NJ

Frequently Asked Questions

What product was recalled?
Ranitidine Capsules 150 mg, (a) 60 count bottles (NDC 62559-690-60) , (b) 500 count bottles (NDC 62559-690-05), Rx only, Manufactured by: Appco Pharma LLC, Piscataway, NJ 08854, Distributed by: ANI Pharmaceuticals, Inc., Baudette, MN 56623.. Recalled by Appco Pharma LLC. Units affected: 624 bottes.
Why was this product recalled?
CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API
Which agency issued this recall?
This recall was issued by the FDA Drug on January 15, 2020. Severity: Moderate. Recall number: D-0649-2020.